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Abstract 
Objectives: Different associations between Single Nucleotide Polymorphisms (SNPs) in 
cellular target, metabolism enzymes or transport proteins, and biopsy proven acute rejection 
(BPAR) or adverse events have been reported in transplant patients receiving mycophenolate 
mofetil (MMF). This work aimed at studying them all in patients on enteric-coated 
mycophenolate sodium (EC-MPS). Methods: The study included 189 renal transplant 
patients from the DOMINOS trial. Fifteen SNPs in IMPDH2, IMPDH1, ABCC2, SLCO1B3, 
UGT1A8, UGT1A9, UGT2B7, CYP2C8, HUS1 and IL12A were genotyped in all patients. 
Associations between SNPs and the first event of BPAR or diarrhea were investigated using 
multivariate logistic regressions. Associations between SNPs and leucopenia or anemia at 9 
different visits between days 0 and 190 post-transplantation, were studied using time 
dependent Cox proportional hazards regression models. Results: Multivariate analyses 
showed that the CYP2C8 rs11572076 wild-type genotype was significantly associated with a 
lower risk of leucopenia (GG vs. GA:  HR [95%CI]=0.14[0.03,0.59]; p=0.00783). Higher EC-
MPS doses and the UGT2B7 c.-840 G>A variant allele were associated with an increased risk 
of anemia (EC-MPS per unit dose increase: 1.004[1.003-1.005], p<0.0001; UGT2B7 GA vs. 
AA: 1.65 [1.12-2.43], p=0.01043; GG vs. AA: 1.88 [1.23-2.88], p=0.00343). However, no 
significant association was found between any of the SNPs studied and diarrhea or BPAR. 
Conclusions: Two pharmacogenetic associations previously reported with MMF were found 
in a population of 189 renal transplant patients treated with EC-MPS.  
 Keywords: pharmacogenetics, mycophenolate sodium, BPAR, adverse effects 
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Introduction 
The enteric-coated formulation of mycophenolate sodium (EC-MPS) has been developed with 
the aim of improving the gastro-intestinal tolerability of mycophenolic acid (MPA). Contrary 
to mycophenolate mofetil (MMF) for which many studies on potential associations between 
pharmacogenetics and pharmacokinetic or pharmacodynamic characteristics have been 
performed, no such study had been reported for EC-MPS so far. 
Due to its particular formulation, the absorption phase of EC-MPS is different from that of 
MMF. Indeed, for EC-MPS the delayed absorption of MPA results in delayed entero-hepatic 
recirculation and subsequently higher and more variable MPA trough levels compared with 
MMF [1]. However, there are no differences regarding their inhibitory effect on inosine 
mono-phosphate dehydrogenases (IMPDH) I and II, two enzymes involved in the de novo 
purine synthesis [2]. MPA is metabolized by glucuronidation in a major, inactive metabolite, 
mycophenolate-phenyl-glucuronide (MPAG). This reaction is catalyzed by UDP-
glucuronosyl–transferases (UGT), particularly UGT1A9 in the kidney and the liver and 
UGT1A8 in intestinal cells [3, 4]. UGT2B7 produces a minor metabolite, mycophenolate-
acyl-glucuronide (AcMPAG) [5], which is highly reactive [6] and might be implicated in 
adverse events, although not in MPA activity [7] . MPAG is mainly eliminated by the kidney 
[8], probably involving the MRP2 drug transporter [9]. However, it is also subject to biliary 
excretion by the active, vectorial transport system OATP and MRP2 [10, 11]. Part of MPAG 
then undergoes bacterial deglucuronidation in the intestine back to MPA, which is then 
reabsorbed [8] giving rise to MPA entero-hepatic cycling. 
Many association studies have been performed between SNPs in genes coding MPA 
metabolism (UGTs), transport (MRP2 and OATPs) or target proteins (IMPDH) on the one 
hand, and biopsy-proven acute rejection (BPAR) or the most frequent adverse effects of MPA 
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(diarrhea, anemia and leucopenia) on the other hand. However, these studies were all 
conducted with MMF as the administered drug and lead to contradictories results [12-14]. 
Moreover, none considered all these different genes simultaneously. 
Recently, Jacobson et al observed in 978 renal transplants that single-nucleotide 
polymorphisms in interleukin IL 12A (IL12A; rs568408 G>A), cytochrome P450 (CYP) 2C8 
(CYP2C8; rs11572076 G>A), and checkpoint homolog protein (HUS1; rs1056663 C>T) were 
associated with the occurrence of mycophenolic acid (MPA)-related anemia but not 
leucopenia [15]. Similarly, Bouamar et al observed in the fixed-dose group of the FDCC 
study (n=178) that the CYP2C8 (rs11572076 G>A) variant allele was significantly associated 
with an increased risk of anemia and leucopenia [16].  
The present work aimed at studying the effect of SNPs in MPA target, metabolism and 
transport proteins on BPAR, diarrhea, anemia and leucopenia in adult kidney transplant 
recipients on EC-MPS. 
 
Methods 
Patients and data 
Patients (n=189) of the DOMINOS study [17] were enrolled in this sub-study after they had 
signed a specific written informed consent for the pharmacogenetic analyses involved. 
DOMINOS was a multicentre, randomized, parallel group, open-label 6-month trial 
conducted in 14 transplant centers in France between April 2007 and March 2009. The study 
was undertaken in accordance with the Declaration of Helsinki and the ICH Harmonized 
Tripartite Guidelines for Good Clinical Practice, ethically approved by the Comité de 
Protection des Personnes (Poitiers) and authorized by the French Drug Agency (AFSSAPS). 
Briefly, in this study adult renal transplant patients treated with cyclosporine (CsA) and EC-
MPS received 2160 mg/day MPS from the day of transplantation to week 6, and then the dose 
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was reduced to 1440 mg/day. Cyclosporine concentration was adjusted based on C2 blood 
levels. Patients were randomized into two arms: one with steroid avoidance (patients only 
received 250 mg intravenous methylprednisolone on day 0 and 1) and a control group where 
patients received corticosteroids until the third month posttransplantation, after which the 
physician had the possibility to stop. At month 6, 38.1% and 86.6% of the patient actually 
received corticosteroids in the steroid avoidance and the control groups, respectively.  Study 
visits were performed on days 1, 3, 5 and 7, weeks 2 and 4 and months 3 and 6 
posttransplantation and laboratory test results (leukocyte counts, hemoglobin levels), CsA C2 
levels, steroid and EC-MPS doses were collected. A kidney biopsy was performed in case of 
suspected rejection, and a blinded central review of all biopsy samples was performed at the 
end of the study. In the present study, we considered as BPAR biopsies with evidence of 
cellular acute rejection or with borderline lesions. In order to exclude the variability in the 
definition of diarrhea, only the diarrhea episodes leading to EC-MPS dose reduction or 
prolonged hospitalization were considered. Mycophenolate-related anemia was defined as the 
use of mycophenolic acid for at least 14 days prior to a hemoglobin level <10g/dL and/or 
initiation of erythropoietin therapy within 30 days of the onset of anemia. Attributable 
leucopenia was defined as the use of mycophenolate at least for 14 days prior to a leucocyte 
count <3 G/L and/or initiation of granulocyte colony stimulating factor or granulocyte-
macrophage colony stimulating factor therapy within 30 days of the onset of leucopenia.  
SNP selection and identification of genotypes 
Genomic DNA was extracted from EDTA-treated blood using the QIAamp DNA Blood Mini 
kit (QIAGEN S.A., Courtaboeuf, France). For all patients, we genotyped the following SNPs: 
IMPDH2 (IVS7+10 T>C, rs11706052); IMPDH1 (rs2278923 and rs2278924); ABCC2 (c.-24 
C>T, rs717620); ABCC2 (c.1249 G>A, rs2273697); ABCC2 (c.3972 C>T, rs3740066); 
ABCC2 (c.4544 G>A, rs8187710); SLCO1B3 (c.334 T>G, rs4149117); UGT1A8 (c.518 C>G, 
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rs1042597); UGT1A9 (c.-2152 C>T rs17868320 and c.-275 T>A rs6714486); UGT2B7 (c.-
840 G>A, rs7438135); CYP2C8 (G>A rs11572076); HUS1 (G>A rs1056663); IL12A (G>A 
rs568408). Genotyping was performed using the TaqMan Real-Time Polymerase Chain 
Reaction discrimination assay on an ABI PRISM 7000 Sequence Detection System (Applied 
Biosystems, Courtaboeuf, France) or a Rotorgene-Q (Qiagen, Courtaboeuf, France) following 
the manufacturer’s protocol. Assays were ordered from Life-Technologies as functionally 
tested assays (references C__1842928_10, C__15966663_10, C__15966664_10, 
C___2814642_10, C__25639181_40, C__11742072_10, C__34418857_10, 
C__27843087_10, C__26058102_10, C__31658115_10, C__1825446_20, C__2423981_10, 
C__11214910_20) or custom TaqMan SNP genotyping assays (Assays ID: AHBKDMW 
(rs2273697) and AHI12PD (rs8187710). 
Statistical analysis  
The statistical analyses were performed using R software version 2.13.1 (R foundation for 
statistical computing, http://www.r-project.org). Deviations from Hardy–Weinberg 
equilibrium were assessed using the Fisher exact test with the package ‘SNPassoc’. 
SNPs were recoded following dominant, recessive or co-dominant genetic models, as a 
function of their frequency and of literature results.  
In order to study the impact of the time-dependent CsA exposure on time-independent 
phenotypes (BPAR and diarrhea), the global exposure of each individual to CsA was 
computed as the area under the curve of all the available C2 levels in the period of follow-up 
(AUCC2 = equivalent to (mean C2)×follow-up duration). The EC-MPS cumulative dose 
(CDEC-MPS = (mean EC-MPS dose)×follow-up duration) was calculated in the same way. In a 
first step, the association between BPAR, diarrhea and each SNP, exposure index or 
demographic variable was studied by univariate analysis using logistic regression. The 
potential associations of SNPs, EC-MPS daily dose at each visit, patient randomization group 
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(with vs. without steroids) and demographic data (age and sex) with time-dependent 
phenotypes, such as leucopenia and anemia were investigated by univariate analysis using 
time-dependent Cox proportional hazards regression models.  
For multivariate analyses, all the variables leading to p<0.1 at this step were then included 
together in an intermediate model. The final model was selected by a backward stepwise 
selection process based on the Bayesian Information criterion (BIC).  
 
 
Results 
Clinical data 
The characteristics of the 189 patients included in this pharmacogenetic sub-study are 
presented in Table 1. A total of 46 (27%) patients were diagnosed with BPAR, out of 168 
patients with such data available. Eight patients had 2 BPAR events, which led to a total of 54 
BPAR episodes. The 21 patients with no biopsy results were completely at random. A total of 
15 (8.6%) patients out of the 189 patients had at least one diarrhea episode. Among them, 2 
patients had 2 diarrhea events, which led to a total of 17 diarrhea episodes. Twenty three 
episodes of leucopenia were found in 19 patients, among the 1398 data available over 9 visits. 
A hundred seventy five episodes of anemia were found in 98 patients, among the 1279 data 
available over 9 visits. In the present substudy, 9 patients (9.6%) in the steroid avoidance 
group were actually given corticosteroids in the course of the study, based on clinician 
decision. All the SNPs respected the Hardy Weinberg equilibrium. 
BPAR and pharmacogenetic associations 
No significant association was found between SNP, age, sex, randomization group, CDEC-MPS, 
AUCC2 and BPAR in univariate or multivariate analysis (Table 2).  
Diarrhea and pharmacogenetic associations 
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Univariate analysis showed that no genetic covariate was significantly associated with 
diarrhea (Table 3), but suggested that diarrhea episodes were more frequent in female 
patients. This factor was kept in the final model, with increased risk of diarrhea in females (F 
vs. M: OR (95%CI) = 3.11 (1.05-9.15); p=0.040) 
Leucopenia and pharmacogenetic associations 
Univariate analysis of leucopenia (Table 4) showed that IMPDH2 rs11706052, IMPDH1 
rs2278923, ABCC2 rs3740066 and CYP2C8 rs11572076 had a p value < 0.1. However, only 
the CYP2C8 rs11572076 was retained in the final, multivariate model, with a lower risk of 
leucopenia in carriers of the wild-type genotype (GG vs. GA:  HR [95%CI] = 0.14 [0.03-
0.59]; p=0.00783).   
 
Anemia and pharmacogenetic associations 
Univariate analysis of anemia (Table 5) showed that EC-MPS dose, ABCC2 -24 C>T, 
UGT1A9 -275T>A and UGT2B7 -840 G>A had a p value < 0.1. Multivariate analyze only 
retained EC-MPS dose (per unit dose increase: HR [95%CI]: 1.004 [1.0035-1.0047], 
p<0.0001) and UGT2B7 c.-840 G>A variant allele (GA vs. AA: 1.65 [1.12-2.43], p=0.01043; 
GG vs. AA: 1.88 [1.23-2.88], p=0.00343) as significantly associated with an increased risk of 
anemia.  
 
Discussion 
This study investigating potential associations between polymorphisms in target, metabolism 
or transport proteins of mycophenolate sodium and drug-related clinical events in kidney 
transplant recipients. The result showed that there was no association between any SNP or 
EC-MPS dose on BPAR, there was a significant influence of: female gender on the risk of 
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diarrhea; CYP2C8 rs11572076 G>A on leucopenia and UGT2B7 c.-840 G>A variant allele 
and EC-MPS dose on anemia. 
In the present study, patient exposure to the immunosuppressants was taken into account as 
the time-weighted mean value (AUC of (EC-MPS dose or cyclosporine C2) per time unit). 
This approach is not common and has not been, to our knowledge, applied and validated 
previously. Usually, to take into account the level of immunosuppression, authors test the 
effect of CsA C2 or EC-MPS dose at each protocol visit. However, it increases the number of 
tests and thus the alpha risk, and it considers each period independently, so that the influence 
of slight underexposure or overexposure for long periods of time will not be detected. As a 
consequence, little is known about the relationships between immunosuppressant exposure (in 
terms of Cmax, Cmin, AUC, cumulated exposure, nadir values, etc.) over time and clinical 
phenotypes. Another advantage of estimating time-weighted mean exposure is that it is 
compatible with missing data and is easier than modelling multiple time occurrences, which 
requires describing the relationships between observations at different times. A limitation may 
be that such an exposure index obviously dampens local variations. However, in the context 
of a pharmacogenetic study, our goal was not to investigate the direct associations between 
immunosuppression highs or lows and clinical phenotypes, but rather to take into account 
overall exposure as a covariate, if pertinent. We are working on different approaches to such 
estimation of global exposure and its association with clinical outcomes, one of which has 
been submitted for publication elsewhere.  
In the present study, no association was found between CsA C2 and BPAR. As already 
mentioned above, a limitation may be that such an exposure index obviously averages local 
variations. It seems that initial studies showed a benefit of C2 monitoring; however, recent 
studies questioned this benefit [18].  
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In the present ancillary study, we considered BPAR and borderline lesions together, which 
partly explains the high percentage of BPAR obtained. When we consider only acute 
rejection, there were 37 episodes (=22%), but this is still quite high and we have no 
explanation for this. We cannot exclude a selection bias by which clinicians would have 
encouraged more patients with rejection to participate in this pharmacogenetic substudy. Such 
a selection bias, if any, would increase the statistical power of our tests but would not bias the 
gene-outcome association found. .   
Stern et al reported that female Sprague-Dawley rats treated chronically with oral MPA had 
more GI toxicity than male rats and that intestinal microsomes from the upper jejunum of the 
female rats had 3-fold lower MPA glucuronidation rates than males [19]. The authors made 
the hypothesis that the greater susceptibility of female rats to diarrhea could thus result from 
reduced protection of enterocytes by in situ glucuronidation. This is consistent with the 
present finding of a significant association between female gender and increased risk of 
diarrhea. A possible limitation to this finding is that different attitudes of females and males 
with respect to diarrhea declaration to the physician could have led to a false association 
between diarrhea and sex. However, by choosing a conservative definition of diarrhea 
(requiring EC-MPS dose reduction or prolonging hospitalization), we hope we minimized this 
reporting bias, if any. Such an effect of sex on diarrhea was not found in the princeps study 
and in the clinical trials with EC-MPS [1, 17, 20], maybe because it was not investigated, or 
maybe because it is a spurious result here. It would be of interest to analyze in more detail the 
results of previous trials to confirm or turn down this apparent association. It must also be 
admitted that it could be chance finding in our study, owing to an imbalance between the 
different risk factors of diarrhea between males and females. In any case, we do not think that 
this finding could lead to clinical recommendations. 
  
11 
 
The CYP2C8 rs11572076 variant allele has been previously associated with an increased risk 
of leucopenia in the fixed dose arm of the FDCC study [16]. This may be partly influenced by 
a decreased of MPA metabolism associated to the CYP2C8 variant allele and to a higher 
exposure to MPA, which is well known to favor leucopenia [21]. However, it is rather 
unlikely that this SNP could explain on its own such an increased in MPA exposure given the 
minor involvement of this enzyme in MPA metabolism [22]. It is of note that there was no 
difference in EC-MPS dose between CYP2C8 genotype groups (data not shown), as 
confirmed by the non-significant statistical interaction between the CYP2C8 SNP and EC-
MPS dose.  
In contrast to the results reported by Jacobson et al. [15], no effect of HUS1 on anemia was 
observed. The major difference between their study and the present one was the galenic form 
of mycophenolate (EC-MPS vs. MMF), but it may not be sufficient to explain this 
discrepancy. Another possible explanation could be an insufficient statistical power in the 
present study to detect such an effect on anemia. However, another group did not observe any 
impact of this polymorphism on anemia despite a larger group of renal transplant patients 
[16]. 
An increasing risk of anemia was found with increasing doses of EC-MPS. These results are 
in conformity with one of the phase 3 MMF studies, which found that MMF dosing was 
related to anemia [23]. In this study, we also found an increased risk of anemia in carriers of 
the UGT2B7 c.-840 G>A variant allele. A previous study performed in our team found a 
higher AcMPAG area under the curve in patient carriers of this UGT2B7 c.-840 G>A variant 
allele [24]. Moreover, higher AcMPAG AUCs were reported to be significantly associated 
with an increased risk of anemia in thoracic transplantation [25]. A possible explanation of 
this relationship between the UGT2B7 c.-840 G>A variant allele and anemia could thus be the 
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increased production of AcMPAG, with high reactive properties [26] leading to a chronic 
inflammation and anemia.  
A general limitation of this study is that MPA exposure was not measured. Indeed, the EC-
MPS formulation is associated with a higher intra- and inter-patient variability in MPA 
exposure than MMF at equivalent doses [1, 27]. Thus, EC-MPS dose cannot be considered the 
best marker of MPA exposure.  
 
In conclusion, in a population of 189 renal transplant patients treated with EC-MPS, two 
pharmacogenetic associations previously reported with MMF were found. The clinical 
implementation of pharmacogenetic markers would be of particular interest for this particular 
formulation, which has a hardly predictable pharmacokinetics. However, it is premature to 
recommend such genotyping in routine practice because the exact mechanisms behind these 
findings are still unclear. These results have to be confirmed by independent studies. 
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Table 1- Demographic, treatment and genetic characteristics of the 189 patients included in 
the DOMINOS pharmacogenetic substudy (continuous data are expressed as mean±sd). 
 
Variable Value 
Age (years) 51 ± 11 
Cyclosporine AUCC2* (mg*month/L) 1156 ± 275 
CDEC-MPS** (mg/month) 1568 ± 195 
Randomization group 
(number without steroids/with steroids) 
 
94/95 
BPAR yes/no 42/126 
$Diarrhea yes/no 15/174 
Anemia yes/no 175/1279 
Leucopenia yes/no 23/1398 
Male/Female 124/65 
IMPDH2 IVS7+10 T>C (rs11706052) 
TT 
TC 
CC 
 
151 (80%) 
36 (19%) 
2 (1%) 
IMPDH1 C>T (rs2278923) 
CC 
CT 
TT 
 
52 (28%) 
97 (51%) 
40 (21%) 
IMPDH1 C>T (rs2278924) 
CC 
CT 
TT 
 
85 (45%) 
84 (44%) 
20 (11%) 
ABCC2 -24 C>T (rs717620) 
CC 
CT 
 
124 (66%) 
65 (34%) 
ABCC2 1249 G>A (rs2273697) 
GG 
GA 
AA 
 
120 (64%) 
57 (30%) 
12 (6%) 
ABCC2 3972 C>T (rs3740066) 
CC 
CT 
TT 
 
71 (38%) 
87 (46%) 
31 (16%) 
ABCC2 4544 G>A (rs8187710) 
GG 
GA 
AA 
 
161 (85%) 
26 (14%) 
2 (1%) 
SLCO1B3 334 T>G (rs4149117) 
TT 
TG 
GG 
 
5 (3%) 
45 (24%) 
139 (73%) 
UGT1A8 518 C>G (rs1042597) 
CC 
 
111 (59%) 
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CG 
GG 
62 (33%) 
16 (8%) 
UGT1A9 -2152 C>T (rs17868320) 
CC 
CT 
 
177 (94%) 
12 (6%) 
UGT1A9 -275 T>A (rs6714486) 
TT 
TA 
AA 
 
170 (90%) 
18 (9%) 
1 (1%) 
UGT 2B7 -840 G>A (rs7438135) 
GG 
GA 
AA 
 
45 (24%) 
86 (45%) 
58 (31%) 
CYP2C8 G>A (rs11572076) 
GG 
GA 
 
187 (99%) 
2 (1%) 
HUS1 (rs1056663) 
GG 
GA 
AA 
 
58 (31%) 
91 (48%) 
40 (21%) 
IL12A (rs568408) 
GG 
GA 
AA 
 
154 (82%) 
33 (17%) 
2 (1%) 
* (mean C2)×follow-up duration ; **(mean EC-MPS dose)×the follow-up period duration;  $ 
diarrhea episodes leading to EC-MPS dose reduction or prolonged hospitalization; for BPAR 
and diarrhea, the first episode was taken into account, for anemia and leucopenia, the total 
number of events among the whole protocol visits were taken into account.
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 Table 2- Results of univariate logistic regressions of potential factors favoring the first 
biopsy-proven acute rejection (BPAR) 
Covariate Category OR (95%CI) p 
CDEC-MPS* 
(mg*month) 
Per unit  increase 0.999 (0.997,1.001) 0.708 
Cyclosporine 
AUCC2** 
(mg*month/L) 
Per unit increase 1.000 (0.999,1.001) 0.594 
Age Per year increase 0.99 (0.96,1.02) 0.542 
Sex M vs. F 1.22 (0.61,2.47) 0.571 
Randomization group 
with vs. without 
steroids 
0.98 (0.5,1.93) 0.951 
IMPDH2 IVS7+10 
T>C (rs11706052) 
 
TT vs TC/CC 1.35 (0.56,3.24) 0.501 
IMPDH1 C>T 
(rs2278923) 
 
CT vs. CC 
TT vs. CC 
0.94 (0.43,2.06)  
0.87 (0.33,2.30) 
0.883 
0.772 
IMPDH1 C>T 
(rs2278924) 
 
CT vs. CC 
TT vs. CC 
0.83 (0.4,1.7)  
0.94 (0.3,2.93) 
0.606 
0.910 
ABCC2 -24 C>T 
(rs717620) 
CT vs. CC 0.95 (0.46,1.92) 0.877 
ABCC2 1249 G>A 
(rs2273697) 
GG vs. GA/AA  1.65 (0.79,3.44) 0.185 
ABCC2 3972 C>T 
(rs3740066) 
CT vs. CC 
TT vs. CC 
1.36 (0.63,2.97) 
2.31 (0.88,6.05) 
0.434 
0.088 
ABCC2 4544 G>A 
(rs8187710) 
GG vs. GA/AA 1.39 (0.52,3.69) 0.513 
SLCO1B3 334 T>G 
(rs4149117) 
TG/TT vs. GG 0.75 (0.34,1.64) 0.472 
UGT1A8 518 C>G 
(rs1042597) 
CG/GG vs. CC 1.04 (0.52,2.05) 0.920 
UGT1A9 -2152 C>T 
(rs17868320) 
 
CC vs. CT 1.36 (0.39,4.74) 0.632 
UGT1A9 -275 T>A TT vs. TA/AA 0.55 (0.20,1.52) 0.252 
UGT2B7 -840 G>A 
(rs7438135) 
 
GA vs. AA 
GG vs. AA 
1.54 (0.7,3.41)  
0.89 (0.34,2.33) 
0.282 
0.808 
CYP2C8 G>A 
rs11572076 
GG vs. GA 0.37 (0.02,6.07) 0.488 
HUS1 G>A 
rs1056663 
GA vs. AA 
GG vs. AA 
1.15 (0.46,2.83)  
1.35 (0.52,3.49) 
0.767 
0.542 
IL12A G>A 
rs568408 
GG vs. GA/AA 0.66 (0.29,1.51) 0.326 
*(mean EC-MPS dose)×the follow-up period duration ; ** (mean C2)×follow-up duration 
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Table 3- Results of univariate logistic regressions of potential factors favoring the first 
diarrhea episode leading to EC-MPS dose reduction or prolonged hospitalization 
 
Covariate Category OR (95%CI) p 
CDEC-MPS* (mg*month) Per  unit increase 1.00 (0.997,1.003) 0.979 
Cyclosporine AUCC2** 
(mg*month/L) 
Per unit increase 1.0009(0.999,1.003) 0.351 
Age Per year increase 1.01 (0.96,1.06) 0.604 
Sex F vs M 3.11(1.05,9.15) 0.040 
Randomization group 
with vs. without 
steroids 
2.09 (0.69,6.38) 0.193 
IMPDH2 IVS7+10 T>C 
(rs11706052) 
TT vs. TC/CC 1.00 (0.27,3.74) 1 
IMPDH1 C>T (rs2278923) 
TC vs. CC 
TT vs. CC 
0.40 (0.10,1.58) 
1.61 (0.45,5.71) 
0.192 
0.460 
IMPDH1 C>T (rs2278924) 
TC vs. CC 
TT vs. CC 
0.42 (0.12,1.43) 
0.89 (0.18,4.46) 
0.166 
0.886 
ABCC2 -24 C>T 
(rs717620) 
CT vs. CC 0.46 (0.12,1.68) 0.237 
ABCC2 1249 G>A 
(rs2273697) 
GG vs. GA/AA  1.67 (0.51,5.44) 0.399 
ABCC2 3972 C>T 
(rs3740066) 
CT vs. CC 
TT vs. CC 
0.82 (0.23,2.94) 
2.58 (0.69,9.64) 
0.757 
0.160 
ABCC2 4544 G>A 
(rs8187710) 
GG vs. GA/AA 2.67 (0.34,21.1) 0.353 
SLCO1B3 334 T>G 
(rs4149117) 
TT/TG vs. GG 1.02 (0.31,3.36) 0.974 
UGT1A8 518 C>G 
(rs1042597) 
CG/GG vs. CC 1.28 (0.44,3.69) 0.646 
UGT1A9 -2152 C>T 
(rs17868320) 
CT vs. CC 1.06 (0.13,8.86) 0.954 
UGT1A9 -275 T>A TT vs. AA/TA 1.61 (0.20,12.93) 0.657 
UGT2B7 -840 G>A 
(rs7438135) 
GA vs. AA 
GG vs. AA 
3.23 (0.67,15.53) 
2.73 (0.48,15.63) 
0.143 
0.259 
CYP2C8 G>A rs11572076 GG vs. GA Inf (0,Inf) 0.993 
HUS1 G>A rs1056663  
GA vs. AA 
GG vs. AA 
0.74 (0.2,2.69) 
0.67 (0.16,2.84) 
0.649 
0.583 
IL12A G>A rs568408 GG vs. GA/AA 3.38 (0.43,26.57) 0.248 
*(mean EC-MPS dose)×the follow-up period duration ; ** (mean C2)×follow-up duration 
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Table 4- Univariate analysis of factors influencing leucopenia using time dependent Cox 
proportional hazards regression models. The total number of events among the whole protocol 
visits were studied. 
 
*Covariate Category HR (95%CI) p value 
EC_MPS dose Per unit increase 0.999 (0.998,1.000) 0.2220 
Age Per year increase 1.03 (0.99,1.07) 0.1400 
Sex F vs M 1.66 (0.73,3.76) 0.2270 
Randomization group 
with vs. without 
steroids 
0.61 (0.27,1.38) 0.2380 
IMPDH2 IVS7+10 
T>C (rs11706052) 
TT vs. TC/CC 6.14 (0.83,45.58) 0.0761 
IMPDH1 C>T 
(rs2278923) 
CT vs. CC 
TT vs. CC 
4.84 (1.12,20.97) 
3.35 (0.65,17.33) 
0.0351 
0.1489 
IMPDH1 C>T 
(rs2278924) 
CT vs. CC 
TT vs. CC 
1.42 (0.60,3.34) 
0.98 (0.21,4.56) 
0.4200 
0.9770 
ABCC2 -24 C>T 
(rs717620) 
CT vs. CC 0.83 (0.35,2.02) 0.6890 
ABCC2 1249 G>A 
(rs2273697) 
GG vs. GA/AA  0.89 (0.39,2.03) 0.7880 
ABCC2 3972 C>T 
(rs3740066) 
CT vs. CC 
TT vs. CC 
0.42 (0.14,1.23) 
2.45 (0.99,6.07) 
0.1147 
0.0533 
ABCC2 4544 G>A 
(rs8187710) 
GG vs. GA/AA 4.82 (0.65,35.81) 0.1240 
SLCO1B3 334 T>G 
(rs4149117) 
TG/TT vs. GG 1.60 (0.70,3.65) 0.2620 
UGT1A8 518 C>G 
(rs1042597) 
CG/GG vs. CC 1.64 (0.73,3.67) 0.2270 
UGT1A9 -2152 C>T 
(rs17868320) 
CT vs. CC 0 (0,Inf) 1.0000 
UGT1A9 -275 T>A TT vs. TA/AA 2.38 (0.32,17.67) 0.3970 
UGT 2B7 -840 G>A 
(rs7438135) 
GA vs. AA 
GG vs. AA 
0.57 (0.22,1.46) 
0.69 (0.24,1.99) 
0.2430 
0.4910 
CYP2C8 G>A 
rs11572076 
GG vs. GA 0.14 (0.03,0.59) 0.0078 
HUS1 G>A 
rs1056663 
GA vs. AA 
GG vs. AA 
0.70 (0.23,2.08) 
1.07 (0.36,3.21) 
0.5180 
0.9000 
IL12A G>A 
rs568408 
GG vs. GA/AA 0.55 (0.22,1.41) 0.2140 
 
*cyclosporine C2 was not evaluated due to a high number of missing values (487/1398), 
totally at random
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Table 5- Univariate analysis of factors influencing anemia using time dependent Cox 
proportional hazards regression models. The total number of events among the whole protocol 
visits were studied. 
  
Covariate Category HR (95%CI) p value 
EC_MPS dose Per unit increase 1.004 (1.003,1.005) <0.0001 
Age Per year increase 1.003(0.989, 1.016) 0.690 
Sex F vs M 0.95 (0.69,1.31) 0.768 
Randomization group 
with vs. without 
steroids 
0.83 (0.61,1.11) 0.207 
IMPDH2 IVS7+10 
T>C (rs11706052) 
TT vs. TC/CC 1.11 (0.77,1.62) 0.572 
IMPDH1 C>T 
(rs2278923) 
CT vs. CC 
TT vs. CC 
0.95 (0.67,1.34) 
1.09 (0.72,1.63) 
0.769 
0.682 
IMPDH1 C>T 
(rs2278924) 
CT vs. CC 
TT vs. CC 
0.99 (0.72,1.36) 
1.12 (0.70,1.80) 
0.958 
0.630 
ABCC2 -24 C>T 
(rs717620) 
CT vs. CC 1.42 (1.06,1.92) 0.0202 
ABCC2 1249 G>A 
(rs2273697) 
GG vs. GA/AA  1.14 (0.83,1.56) 0.4170 
ABCC2 3972 C>T 
(rs3740066) 
CT vs. CC 
TT vs. CC 
1.35 (0.97,1.89) 
1.43 (0.91,2.25) 
0.0772 
0.1235 
ABCC2 4544 G>A 
(rs8187710) 
GG vs. GA/AA 0.77 (0.53,1.12) 0.1790 
SLCO1B3 334 T>G 
(rs4149117) 
TG/TT vs. GG 1.14 (0.82,1.58) 0.447 
UGT1A8 518 C>G 
(rs1042597) 
CG/GG vs. CC 1.02 (0.75,1.37) 0.914 
UGT1A9 -2152 C>T 
(rs17868320) 
 
CT vs. CC 1.54 (0.85,2.76) 0.150 
UGT1A9 -275 T>A TT vs. TA/AA 0.65 (0.43,0.99) 0.0473 
UGT 2B7 -840 G>A 
(rs7438135) 
 
GA vs. AA 
GG vs. AA 
1.51 (1.03,2.22) 
1.63 (1.07,2.50) 
0.036 
0.023 
CYP2C8 G>A 
rs11572076 
GG vs. GA 1.88 (0.26,13.43) 0.529 
HUS1 G>A 
rs1056663 
GA vs. AA 
GG vs. AA 
0.76 (0.52,1.12) 
0.89 (0.59,1.33) 
0.162 
0.567 
IL12A G>A 
rs568408 
GG vs. GA/AA 0.98 (0.66,1.43) 0.905 
*cyclosporine C2 was not evaluated due to a high number of missing values (514/1279), 
totally at random 
 
 
